Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why?

World J Gastroenterol. 2024 Feb 7;30(5):509-511. doi: 10.3748/wjg.v30.i5.509.

Abstract

The risk of reactivation in patients with chronic or past/resolved hepatitis B virus (HBV) infection receiving chemotherapy or immunosuppressive drugs is a well-known possibility. The indication of antiviral prophylaxis with nucleo(t)side analogue is given according to the risk of HBV reactivation of the prescribed therapy. Though the advent of new drugs is occurring in all the field of medicine, in the setting of hematologic malignancies the last few years have been characterized by several drug classes and innovative cellular treatment. As novel therapies, there are few data about the rate of HBV reactivation and the decision of starting or not an antiviral prophylaxis could be challenging. Moreover, patients are often treated with a combination of different drugs, so evaluating the actual role of these new therapies in increasing the risk of HBV reactivation is difficult. First results are now available, but further studies are still needed. Patients with chronic HBV infection [hepatitis B surface antigen (HBsAg) positive] are reasonably all treated. Past/resolved HBV patients (HBsAg negative) are the actual area of uncertainty where it could be difficult choosing between prophylaxis and pre-emptive strategy.

Keywords: Antiviral prophylaxis; Chimeric antigens receptor-T cell therapy; Hematologic malignancies; Hepatitis B reactivation; Hepatitis B virus; Immune checkpoint inhibitors.

MeSH terms

  • Antiviral Agents / adverse effects
  • Hematologic Neoplasms* / drug therapy
  • Hepatitis B Surface Antigens
  • Hepatitis B virus
  • Hepatitis B* / diagnosis
  • Hepatitis B* / drug therapy
  • Hepatitis B* / prevention & control
  • Humans
  • Virus Activation

Substances

  • Hepatitis B Surface Antigens
  • Antiviral Agents